Genomic Grade is currently available in Europe as MapQuant™, an Affymetrix micro-array based assay.

A PCR version of the test, adapted to formalin fixed-parafin embedded specimens, is under development and should be available end 2011.

Interested in IPSOGEN’s developments in Breast Cancers?
Please contact us.